The anti-GDF15 antibody ponsegromab suppressed serum unbound GDF15 concentrations and was associated with weight gain in patients with advanced cancer in a phase Ib study and led to weight gain and improved cancer cachexia symptoms in patients with cancer in a phase II study (24, 32). This evidence concerns the gene GDF15 and cancer.